Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Autor: Ray AS; Gilead Sciences, Inc., Foster City, CA 94404, USA. Electronic address: adrian.ray@gilead.com., Fordyce MW; Gilead Sciences, Inc., Foster City, CA 94404, USA., Hitchcock MJ; Gilead Sciences, Inc., Foster City, CA 94404, USA.

Publikováno v: Antiviral research [Antiviral Res] 2016 Jan; Vol. 125, pp. 63-70. Date of Electronic Publication: 2015 Nov 27.

Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.

Autor: Keith KA; University of Alabama School of Medicine, Birmingham, Alabama 35233, USA. Kern@uab.edu, Hitchcock MJ, Lee WA, Holý A, Kern ER

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2003 Jul; Vol. 47 (7), pp. 2193-8.

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Autor: Birkus G; Gilead Sciences, Foster City, California 94404, USA., Hitchcock MJ, Cihlar T

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2002 Mar; Vol. 46 (3), pp. 716-23.

Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.

Autor: Cundy KC; Gilead Sciences, Inc., Foster City, CA 94404, USA., Li ZH, Hitchcock MJ, Lee WA

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 1996 Jul; Vol. 24 (7), pp. 738-44.